Regenxbio Inc. (RGNX)
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.72 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to earnings of $0.12 per share a year ago.
REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript
REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.3 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to a loss of $1.01 per share a year ago.
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regenxbio: Cautiously Bullish After FDA Setbacks
REGENXBIO's NAV AAV platform has given them a diversified pipeline. They have RGX-314 and RGX-202 as primary value drivers with promising 2026 catalysts. RGX-314 is being developed in partnership with AbbVie, targeting wet AMD and diabetic retinopathy. These are sizeable TAMs, which could pay off in the long run. RGX-202 also shows promising early Duchenne data and Phase 3 progress. However, we still need to see the trials' long-term efficacy and safety data.
Regenxbio (RGNX) Soars 5.4%: Is Further Upside Left in the Stock?
Regenxbio (RGNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away
Regenxbio Inc. faces pivotal catalysts in 2026, notably RGX-121's FDA decision and RGX-202 Duchenne data, potentially transforming it into a commercial-stage gene therapy company. RGX-121 offers a unique CNS-targeted approach for Hunter syndrome, with strong biomarker and neurodevelopmental data supporting its accelerated approval case ahead of the February 8 PDUFA date. RGNX's valuation appears modest at a 3.3x forward EV/sales multiple, with late-stage assets, near-term regulatory events, and a healthy cash position providing balance sheet flexibility.
REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome
Regenxbio's RGX-121 for Hunter syndrome saw its FDA review delayed to February 8, 2026, but strong 12-month surrogate endpoint data supports its potential as a gene therapy. Late-stage Sura-vec trials for Wet-AMD, in partnership with AbbVie, remain on track for 2026 topline results, bolstering the pipeline's value. Recent partnerships and royalty deals have strengthened Regenxbio's cash position, extending its runway into early 2027 despite ongoing R&D expenses.
REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Curran M. Simpson - President, CEO & Director Mitchell Chan - Executive VP & CFO Patrick J.
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.05 per share a year ago.
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome
REGENXBIO specializes in gene therapies using proven AAV technology. RGX-121, targets Hunter syndrome and is under FDA review, with a PDUFA date set for November 9, 2025. We believe the upcoming FDA decision represents a significant catalyst for RGNX shares, offering a compelling pre-approval investment opportunity.
